Quoin Pharmaceuticals (QNRX) Other Non Operating Income (2021 - 2026)
Quoin Pharmaceuticals (QNRX) posted Other Non Operating Income of -$13300.0 for Q1 2026, down 3753.85% sequentially from $364.0 in Q4 2025, and down 10655.56% YoY from N/an in Q1 2025.
Quoin Pharmaceuticals (QNRX) Other Non Operating Income (2021 - 2026) Analysis & Trends
Quoin Pharmaceuticals has reported Other Non Operating Income for 6 years, with the latest figure at -$13300.0 in Q1 2026.
- Quarterly Other Non Operating Income fell 10655.56% year-over-year to -$13300.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$9446.0 (down 166.82% YoY) and the FY2025 annual result came in at $3980.0, down 46.95% from the prior year.
- Other Non Operating Income fell to -$13300.0 in Q1 2026 per QNRX's latest filing, from $364.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $416000.0 in Q1 2022 and troughed at -$34472.0 in Q2 2023.
- A 5-year average of $31652.9 and a median of $245.0 in 2025 frame the typical range for Other Non Operating Income.
- The sharpest annual moves came in 2024 and 2026: Other Non Operating Income surged 1397.36% in 2024, then plunged 10655.56% in 2026.
- Over 5 years, Other Non Operating Income stood at -$3053.0 in 2022, then jumped by 402.75% to $9243.0 in 2023, then sank by 268.14% to -$15541.0 in 2024, then jumped by 102.34% to $364.0 in 2025, then sank by 3753.85% to -$13300.0 in 2026.
- According to Business Quant data, Other Non Operating Income over the past three periods registered -$13300.0, $364.0, and $9494.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Quoin Pharmaceuticals | 531,643.73 | 531,643.73 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13,300.00 |
| Dec 31, 2025 | 364.00 |
| Sep 30, 2025 | 9,494.00 |
| Jun 30, 2025 | -6,004.00 |
| Mar 31, 2025 | 126.00 |
| Dec 31, 2024 | -15,541.00 |
| Sep 30, 2024 | 31,729.00 |
| Jun 30, 2024 | -2,177.00 |
| Mar 31, 2024 | -6,509.00 |
| Dec 31, 2023 | 9,243.00 |
| Sep 30, 2023 | 2,119.00 |
| Jun 30, 2023 | -34,472.00 |
| Mar 31, 2023 | 20,427.00 |
| Sep 30, 2022 | -3,053.00 |
| Jun 30, 2022 | 98,000.00 |
| Mar 31, 2022 | 416,000.00 |
| Jun 30, 2021 | -750,000.00 |